Purpose: This analysis was conducted to evaluate the efficacy and safety of icotinib based regimens in treatingpatients with non-small cell lung cancer (NSCLC).
Methods: Clinical studies evaluating the efficacy and safetyof icotinib-based regimens with regard to response and safety for patients with NSCLC were identified usinga predefined search strategy. Pooled response rates of treatment were calculated.
Results: With icotinib-basedregimens, 7 clinical studies which including 5,985 Chinese patients with NSCLC were considered eligible forinclusion. The pooled analysis suggested that, in all patients, the positive reponse rate was 30.1% (1,803/5,985)with icotinib-based regimens. Mild skin itching, rashes and diarrhea were the main side effects. No grade III orIV renal or liver toxicity was observed. No treatment-related death occurred in patients treated with icotinibbasedregimens.
Conclusions: This evidence based analysis suggests that icotinib based regimens are associatedwith mild response rate and acceptable toxicity for treating Chinese patients with NSCLC.